Replicor Inc

REPLICor to Present Updated Clinical Trial Data with Combination Treatment Using its HBsAg-release Inhibitors in Patients with Chronic Hepatitis B Infection at the 10th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS)

Montreal (ots/PRNewswire) - Updated clinical trial data from REPLICor's three Asian trials using its nucleic acid polymer (NAP) HBsAg-release inhibitors REP 2055 (REP 9AC) and REP 2139 (REP 9AC') will be presented at the 10th Annual Meeting of the Oligonucleotide Society, to be held from Oct 12-16, 2014 in San Diego, CA.

REPLICor has currently tested its HBsAg-release inhibitor technology in three different clinical trials using different treatment modalities: in monotherapy, in combination with short term immunotherapy and in combination with a complete course of Pegasys(TM). Data presented will demonstrate 1) the unique ability of REPLICor's NAP compounds to completely suppress HBsAg in the blood 2) the effect of HBsAg clearance on dramatically improving the activity of immunotherapy and 3) when used with a full course of Pegasys(TM), NAP therapy has resulted in the establishment of long term SVR in 80% of patients.

Link to the 2014 OTS meeting:

http://www.cvent.com/events/10th-annual-meeting-of-the-oligonucleotide-therapeutics-society/event-summary-a61fb28b01f84906845f05a247fcfb9b.aspx

For more information please contact:

Andrew Vaillant, Ph.D.
Vice President, Operations and Chief Scientific Officer
Tel.: +1-514-862-2271
availlant@replicor.com
 

 


Das könnte Sie auch interessieren: